ARMO BioSciences Presents Data from its Phase 1b Trial in Non-Small Cell Lung Cancer at ESMO Immuno Oncology Congress 2017

REDWOOD CITY, Calif., Dec. 9, 2017 /PRNewswire/ -- ARMO BioSciences, Inc., a late-stage immuno-oncology company, today released additional clinical trial results on its lead investigational immuno-oncology drug AM0010 (pegilodecakin) in non-small cell lung cancer (NSCLC).In 27 NSCLC...